Fulcrum Therapeutics (FULC) PT Raised to $12 at Morgan Stanley
Tweet
Share
E-mailGet Alerts FULC Hot Sheet
Price: $3.84 +2.67%
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 2 | Down: 6 | New: 5
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 2 | Down: 6 | New: 5
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $12.00 (from $11.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Walker & Dunlop (WD) PT Lowered to $55 at Citizens Amid Interest Rate Headwinds
- Citi Downgrades JB Hi-Fi Ltd (JBH:AU) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
